ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - elotuzumab - אבקה להכנת תמיסה מרוכזת לעירוי - elotuzumab 400 mg/vial - elotuzumab

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - nivolumab; relatlimab - תרכיז להכנת תמיסה לאינפוזיה - relatlimab 4 mg/ml; nivolumab 12 mg/ml - nivolumab

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 10 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 15 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 2.5 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - mavacamten - קפסולות - mavacamten 5 mg - mavacamten

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - deucravacitinib - טבליות מצופות פילם - deucravacitinib 6 mg - deucravacitinib

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited - paracetamol 10 mg/ml - solution for infusion - anilides - perfalgan is indicated for the short-term treatment of moderate pain, especially following surgery and for the short-term treatment of fever, when administration by intravenous route is clinically justified by and urgent need to treat pain or hyperthermia and/or when other routes of administration are not possible.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - ipilimumab - תרכיז להכנת תמיסה לאינפוזיה - ipilimumab 5 mg/ml - ipilimumab - ipilimumab - yervoy (ipilimumab) is indicated for the treatment of unresectable or metastatic melanoma.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - dasatinib - טבליות מצופות פילם - dasatinib 100 mg - dasatinib - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.